Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs
Glesatinib demonstrates improved tolerability with new spray dried dispersion formulation;Promising clinical activity observed in NSCLC patients with MET mutations;Early clinical responses indicate sitravatinib an effective inhibitor of RET in NSCLC
View HTML
Toggle Summary Mirati Therapeutics Reports Financial Results And Provides Business Update For The Third Quarter 2016 View HTML
Toggle Summary Mirati Therapeutics Appoints Chris LeMasters To Role Of Executive Vice President And Chief Business Officer View HTML
Toggle Summary Mirati Therapeutics Announces Appointment Of Dr. Bruce L.A. Carter To Board Of Directors View HTML
Toggle Summary Mirati Therapeutics Reports Financial Results And Provides Business Update For The Second Quarter 2016 View HTML
Toggle Summary Mirati Therapeutics Announces Change In Executive Leadership View HTML
Toggle Summary Mirati Therapeutics Provides Progress Update On Current Clinical Trials View HTML
Toggle Summary Mirati Therapeutics To Present At The Jefferies 2016 Healthcare Conference View HTML
Toggle Summary Mirati Therapeutics To Present Abstracts On Pipeline Programs At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting View HTML
Toggle Summary Mirati Therapeutics Reports Financial Results And Business Update For The First Quarter 2016 View HTML